Company Analysis
Sign in

Nkarta, Inc. (NKTX)

Nasdaq: NKTX · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2019
Full chart Alerts Compare
Grade4.5
◀ Past 4.1● Present 6.3▶ Future 3.2
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

7 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Nkarta, Inc.’s names, not what it holds today.

Patents granted
7
7 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 1 in 2024 and none in 2023
Applications published
22
5 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology7
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Nkarta, Inc. its own name
named as the applicant on its applications, in US
0 granted
22 published
Nkarta, Inc. its own name
US, as the owner printed on each patent
7 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Aug 26, 202512,398,187CD19-directed chimeric antigen receptors and uses thereof in immunotherapyBiotechnologyNkarta, Inc.
Jul 8, 202512,351,617Immune cells comprising truncated NKG2D chimeric receptorsBiotechnologyNkarta, Inc.
Jun 18, 202412,012,458Genetically modified natural killer cells for CD70-directed cancer immunotherapyBiotechnologyNkarta, Inc.
Jun 21, 202211,365,236Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapyBiotechnologyNkarta, Inc.
Feb 22, 202211,253,547CD19-directed chimeric antigen receptors and uses thereof in immunotherapyBiotechnologyNkarta, Inc.
Oct 26, 202111,154,575Cancer immunotherapy using CD19-directed chimeric antigen receptorsBiotechnologyNkarta, Inc.
Oct 12, 202111,141,436Immune cells engineered to express CD19-directed chimeric antigen receptors and uses thereof in immunotherapyBiotechnologyNkarta, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388645Immune Cells Comprising Truncated NKG2D Chimeric ReceptorsBiotechnologyNkarta, Inc.
Nov 6, 20252025/0339528SELECTION OF OPTIMAL CELL DONORS AND METHODS AND COMPOSITIONS FOR ENHANCED EXPANSION AND CYTOTOXICITY OF DONOR CELLSBiotechnologyNkarta, Inc.
Oct 16, 20252025/0319185BCMA-DIRECTED CELLULAR IMMUNOTHERAPY COMPOSITIONS AND METHODSMedical technologyNkarta, Inc.
Sep 25, 20252025/0296970CD19-DIRECTED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF IN IMMUNOTHERAPYBiotechnologyNkarta, Inc.
Mar 6, 20252025/0073266DOSING REGIMENS FOR CANCER IMMUNOTHERAPYPharmaceuticalsNkarta, Inc.
Oct 31, 20242024/0360234GENETICALLY MODIFIED NATURAL KILLER CELLS FOR CD70-DIRECTED CANCER IMMUNOTHERAPYBiotechnologyNkarta, Inc.
Oct 31, 20242024/0358758METHODS FOR TREATMENT OF AUTOIMMUNE DISEASESMedical technologyNkarta, Inc.
Oct 10, 20242024/0335536METHODS OF ENGINEERING IMMUNE CELLS FOR ENHANCED POTENCY AND PERSISTENCE AND USES OF ENGINEERED CELLS IN IMMUNOTHERAPYBiotechnologyNkarta, Inc.
Dec 7, 20232023/0390392MULTIPLEX GENE EDITED CELLS FOR CD70-DIRECTED CANCER IMMUNOTHERAPYBiotechnologyNkarta, Inc.
Aug 24, 20232023/0265390ENHANCED EXPANSION AND CYTOTOXICITY OF ENGINEERED NATURAL KILLER CELLS AND USES THEREOFBiotechnologyNkarta, Inc.
What it applied for, 2024 to 2025: Biotechnology 5 · Medical technology 2 · Pharmaceuticals 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton NKTX · research, not advice